Solomon Islands vs Türkiye: Prevalence rate of hypertension in women aged 30-79
Solomon Islands
34.5
in 2019
Türkiye
34.4
in 2019
Solomon Islands rank
127th
Türkiye rank
129th
Prevalence rate of hypertension in women aged 30-79 over time
- Solomon Islands
- Türkiye
How they compare
Solomon Islands currently reports 34.5 against 34.4 in Türkiye, a difference of 0.1.
The two have swapped places 1 time across 30 shared years of data; in 1990 it was Türkiye ahead.
Solomon Islands ranks 127th and Türkiye ranks 129th of 195 countries.
Türkiye has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Solomon Islands | Türkiye | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 26.42 | 42.76 | 16.34 | Türkiye |
| 2000s | 26.58 | 41.17 | 14.59 | Türkiye |
| 2010s | 31.61 | 36.42 | 4.81 | Türkiye |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in women aged 30-79, Solomon Islands or Türkiye?
- Solomon Islands, at 34.5 against 34.4 in Türkiye as of 2019.
- What is the difference in prevalence rate of hypertension in women aged 30-79 between Solomon Islands and Türkiye?
- 0.1, with Solomon Islands ahead.
- How many years of comparable data are there for Solomon Islands and Türkiye?
- 30 years are reported by both, from 1990 to 2019.
- How do Solomon Islands and Türkiye rank globally for prevalence rate of hypertension in women aged 30-79?
- Solomon Islands ranks 127th and Türkiye ranks 129th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in women aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of female population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.